NCT01062256 is a NA clinical trial of Guaifenesin in Infection, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Who is sponsoring NCT01062256?

NCT01062256 is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

What drugs are being tested in NCT01062256?

Interventions in NCT01062256: Placebo, Guaifenesin, Buckwheat Honey.

Is NCT01062256 still recruiting?

NCT01062256 is currently completed. Last updated 20 February 2013.

Are results published for NCT01062256?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2013-02-20 · How we verify

NCT01062256

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Methodology Study to Assess Cough Counts in Subjects With Acute Upper Respiratory Tract Infections

Completed NA Results posted Last updated 20 February 2013

What this trial tests

NA trial testing Placebo in Infection in 265 participants. Completed in 1 February 2010.

Timeline

1 January 2010

Primary endpoint
1 February 2010

1 February 2010

Quick facts

Lead sponsor	Wyeth is now a wholly owned subsidiary of Pfizer
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	265
Start date	1 January 2010
Primary completion	1 February 2010
Estimated completion	1 February 2010
Sites	2 locations across United States

Drugs / interventions tested

Placebo
Guaifenesin (guaifenesin) — full drug profile →
Buckwheat Honey — full drug profile →

Conditions studied

Infection — all drugs for Infection →

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer — full company profile →

Who can join

18 and older, any sex, with Infection. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Cough Bouts Over 4-hour Postdose Period
Time frame: 0 to 4 hours postdose
Cough bouts defined as one or several cough sounds occurring after one inspiration (one explosive bout between inspiration and expiration). Audio recordings made of participants during 4-hour period after dosing. Based on audio recordings, a trained cough counter counted and recorded the number of cough bouts.

Sponsor's own description

The objectives of this study are: a) to assess the feasibility and sensitivity of manually count cough bouts over a 4-hour period; b) to assess the effects of buckwheat honey and guaifenesin 400 mg immediate release tablets compared to placebo on the frequency and severity of acute cough due to upper respiratory tract infection and c) to evaluate the correlation between cough bout frequency and subjective assessments of cough severity. The hypotheses to be tested is that 10 ml of buckwheat honey and 400 mg of immediate release guaifenesin will significantly reduce the frequency and severity of cough compared to placebo over a 4-hour evaluation period.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Guaifenesin

Trials testing the same drug.

NCT07398924 — Vaginal Estradiol and Oral Guaifenesin in Clomiphene Ovulation Induction · NA · completed
NCT02902640 — A Non-Interventional Safety Study of Balsamic Bactrim · completed
NCT02879981 — A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis · completed

Other recruiting trials for Infection

Currently open trials in the same condition.

NCT07358117 — Viral Infections of the Central Nervous System: Diagnosis and Clinical Outcome · active not recruiting
NCT07110636 — Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients · NA · recruiting
NCT06806709 — Reducing Blood Culture Contamination With the Use of a Needle-less Blood Draw Device (The PIVO Trial) · NA · recruiting
NCT06974162 — Metagenomics for Ocular Inflammation · recruiting
NCT07370948 — Study of the Antibiotic-resistance Profile of Enterobacterales Isolated From Rectal Mucosal Buffer of PrEP Subjects · recruiting

Other Wyeth is now a wholly owned subsidiary of Pfizer trials

Trials by the same sponsor.

NCT00909688 — Study to Evaluate Whether BLI-489 Can be Safely Tolerated by Healthy Subjects Given Multiple Doses · Phase 1 · completed
NCT00853749 — Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine · Phase 3 · completed
NCT00894634 — Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents · Phase 1 · completed
NCT00854009 — Study Evaluating Single Doses of BLI-489 in Healthy Japanese Male Subjects · Phase 1 · completed
NCT00837837 — Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01062256 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wyeth is now a wholly owned subsidiary of Pfizer
Last refreshed: 20 February 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01062256.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing